EuroBiotech: More Articles of Note


> Anokion acquired Kanyos Bio and completed a $40 million series B financing. The acquisition gives Anokion ownership of a preclinical antigen-specific treatment for celiac disease. Statement 

> Genfit named Carol Addy as chief medical officer. Addy previously worked at Merck. Release 

> MaaT Pharma hired Emmanuel Prestat as computational biology manager. Prestat used to work at diagnostic business HalioDx. Statement 

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

> Ermium Therapeutics raised a €6.3 million series A round. The French biotech will use money to fund early-stage autoimmune research. Release 

> Kiadis Pharma confirmed it is still on track to bring ATIR101 to market in Europe next year. Statement 

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.